Merck KGaA Profit Helped by Rebif Sales, Forex

German drugmaker Merck KGaA (MRCG.DE) nudged its earnings outlook higher after beating quarterly expectations, helped by higher sales of multiple sclerosis drug Rebif and a strong dollar. Merck said on Tuesday it had seen a "solid top-line performance in all divisions driven especially by strong organic sales growth from (prescription drug unit) Merck Serono and favourable foreign exchange rates". Second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose 14 percent to 747 million euros ($922 million), compared with a forecast for 706 million in a Reuters poll.

Back to news